Strike Pharma is using its proprietary technology for targeted nanoparticle delivery to enable in vivo CAR-T therapy. The lead candidate, STR3/19, is based on a lipid nanoparticle that carries mRNA for an anti-CD19 CAR that is selectively delivered to T cells via an anti-CD3 antibody. This is an off-the-shelf alternative to current CAR-T therapies, that reprogrammes T cells to B-cell depleting CAR-Ts inside the body and that is intended for treatment of B-cell dependent autoimmune disease, such as SLE, and for B-cell lymphoma. Strike Pharma was founded in 2020, has Eir Ventures and Flerie Invest as major shareholders, and is headquartered at Smile Venture Hub, Medicon Village, Lund, Sweden.
Company Details
- Employees
- 20
- Founded
- -
- Address
- Ulls Väg 29c, Uppsala,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Biotechnology, Immunotherapy, Immuno-oncology, Drug Development, Personalized medicine, CAR-T.
- HQ
- Uppsala
Strike Pharma Ab Questions
Strike Pharma Ab's LinkedIn profile is https://se.linkedin.com/company/strike-pharma
Strike Pharma Ab has
20 employees.
View email and phone details for 20
employees at Strike Pharma Ab.
Strike Pharma Ab's industry is
Biotechnology Research
Strike Pharma Ab's top competitors are
Rarity Bioscience,
Ilya Pharma,
Immuneed,
Uic - Uppsala Innovation Centre,
Readily Diagnostics,
Phenaros,
Akiram Therapeutics,
Giddir Ab,
Arguseye,
Mycural Therapeutics.
Strike Pharma Ab's categories are Biotechnology Research
Strike Pharma Ab's founding year is 2020
